- Home
- BCDA vs PETZ Comparison
BCDA vs PETZ Comparison
Compare BCDA & PETZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- PETZ
- Stock Information
- Founded
- BCDA N/A
- PETZ 2002
- Country
- BCDA United States
- PETZ China
- Employees
- BCDA N/A
- PETZ N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- PETZ Steel/Iron Ore
- Sector
- BCDA Health Care
- PETZ Industrials
- Exchange
- BCDA Nasdaq
- PETZ Nasdaq
- Market Cap
- BCDA 9.4M
- PETZ 10.3M
- IPO Year
- BCDA N/A
- PETZ 2017
- Fundamental
- Price
- BCDA $1.92
- PETZ $1.07
- Analyst Decision
- BCDA Strong Buy
- PETZ
- Analyst Count
- BCDA 1
- PETZ 0
- Target Price
- BCDA $25.00
- PETZ N/A
- AVG Volume (30 Days)
- BCDA 93.6K
- PETZ 7.3K
- Earning Date
- BCDA 05-13-2025
- PETZ 05-06-2025
- Dividend Yield
- BCDA N/A
- PETZ N/A
- EPS Growth
- BCDA N/A
- PETZ N/A
- EPS
- BCDA N/A
- PETZ N/A
- Revenue
- BCDA $58,000.00
- PETZ $3,278,453.00
- Revenue This Year
- BCDA N/A
- PETZ N/A
- Revenue Next Year
- BCDA N/A
- PETZ N/A
- P/E Ratio
- BCDA N/A
- PETZ N/A
- Revenue Growth
- BCDA N/A
- PETZ 2.46
- 52 Week Low
- BCDA $1.63
- PETZ $0.99
- 52 Week High
- BCDA $6.15
- PETZ $1.74
- Technical
- Relative Strength Index (RSI)
- BCDA 38.14
- PETZ 44.26
- Support Level
- BCDA $1.73
- PETZ $0.99
- Resistance Level
- BCDA $1.93
- PETZ $1.06
- Average True Range (ATR)
- BCDA 0.13
- PETZ 0.07
- MACD
- BCDA -0.01
- PETZ 0.00
- Stochastic Oscillator
- BCDA 30.95
- PETZ 42.05
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.